Rocket Pharmaceuticals
Cranbury
About Rocket Pharmaceuticals
Rocket Pharmaceuticals is a biotechnology company that is working to develop first-in-class gene therapy treatments for rare and undertreated diseases. The Company's lead program is a lentiviral-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult-to-treat genetic disease that causes bone marrow failure and, in the worst-case scenario, cancer. Additional bone marrow-derived disorders are being studied in preclinical trials, including Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-1 (LAD-1), and Infantile Malignant Osteopetrosis. In addition, the company is working on an AAV-based gene therapy program for an unnamed rare pediatric disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $891.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2023)
- Ticker: nasdaq:RCKT
- Website: rocketpharma.com
- Phone: 646-224-9585
Industries & Categories
Biotechnology, Genetics, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/rocket-pharmaceuticals-112747 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.